NEW
YORK, June 23, 2023 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the
Company), a leader in the development of targeted radiotherapies,
today details the six abstracts accepted for oral and poster
presentation at the upcoming Society for Nuclear Medicine &
Molecular Imaging (SNMMI) 2023 Annual Meeting, which will be held
in Chicago, June 24-27, 2023. These abstracts exhibit the
breadth of Actinium's technological and clinical endeavors over the
past year that are now culminating in targeted radiotherapies
that meaningfully improve the outcomes of cancer patients.
Details of the SNMMI oral presentations:
Presentation Title: Machine learning applications to
optimize dosimetric imaging of I131-apamistamab for bone marrow
conditioning in relapsed/refractory acute myeloid leukemia (R/R
AML)
Session: New Developments in Radiopharmaceutical Therapy
Date and Time: June 25,
5:00pm – 6:15pm CT
Presentation Title: Individualized dosing for
high-dose targeted radiation of hematopoietic cells with Iomab-B
(I131-apamistamab) prior to HCT in relapsed/refractory acute
myeloid leukemia (R/R AML): Safety and efficacy results from the
pivotal phase 3 SIERRA trial
Session: Hematologic Malignancies
Date and Time: June 26,
12:45 PM – 2:00 PM CT
Presentation Title: Administration and radiation
safety of high-dose Iomab-B (I131-apamistamab) demonstrated in
multiple clinical settings: Experience from the large multicenter
phase 3 SIERRA trial for targeted conditioning of patients with
relapsed/refractory AML
Session: Hematologic Malignancies
Date and Time: June 26,
12:45 PM – 2:00 PM CT
Details of the SNMMI poster presentations:
All posters will be accessible for viewing for the entirety of
the conference. The general session is Science Pavilion – Meet the
Authors Session: June 26,
5:15pm – 6:15pm CT
Abstract Title: Organ-specific dosimetry to estimate
potential toxicity thresholds of Actimab-A (lintuzumab-Ac225) used
in combination with venetoclax in relapsed/refractory AML
Track: Molecular Targeting Probes
Date and Time: June 25, 6:30 –
8:30 pm CT
Abstract Title: Relative biological effectiveness of
antibody radioconjugates (ARCs): In vitro dosimetric evaluation to
streamline pre-clinical decision-making
Track: Oncology, Basic and Translational
Date and Time: June 27, 12:30
– 2:00 pm CT
Abstract Title: Streamlining personalized dosimetry
for I131-apamistamab using a Co-57 sheet source to circumvent the
need for radionuclide-specific attenuation correction
Track: Molecular Targeting Probes-Radioactive &
Nonradioactive
Date and Time: June 27, 12:30 – 2:00 pm CT
About Actinium
Actinium develops targeted radiotherapies to meaningfully
improve survival for people who have failed existing oncology
therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an
induction and conditioning agent prior to bone marrow transplant,
and Actimab-A (National Cancer Institute CRADA pivotal development
path), a therapeutic, have demonstrated potential to extend
survival outcomes for people with relapsed and refractory acute
myeloid leukemia. Actinium plans to advance Iomab-B for other
blood cancers and next generation conditioning candidate Iomab-ACT
to improve cell and gene therapy outcomes. Actinium's
technology platform is the basis for collaborations with Astellas
Pharma for solid tumors, AVEO Oncology/LG Chem Life Sciences for
HER3 solid tumors, and EpicentRx for its CD47 targeting agent, and
several internal programs in solid tumors. Actinium holds
more than 200 patents and patent applications.
For more information, please visit:
https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Contact:
Matthew Beck
Vice President Investor Relations & Communications
mbeck@actiniumpharma.com
(917) 415-1750
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actinium-pharma-highlights-six-abstracts-accepted-for-oral-and-poster-presentation-at-the-snmmi-2023-annual-meeting-301860749.html
SOURCE Actinium Pharmaceuticals, Inc.